Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
FDF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Gadoterate Meglumine
1. Magnescope
2. Meglumine Gadoterate (jan)
3. Gadoterate Meglumine (usan)
4. Gadoterate Meglumine [usan]
5. Meglumine Gadoterate [jan]
6. Magnescope (tn)
7. Dotarem (tn)
8. Schembl20420633
9. Gadoterate Meglumine [vandf]
10. Gadoterate Meglumine [usp-rs]
11. Meglumine Gadoterate [who-dd]
12. Ek-5504
13. Gadoterate Meglumine [orange Book]
14. P449
15. P-449
16. D03355
17. Q27144071
18. 2-[4,7-bis(carboxylatomethyl)-10-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+);(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol
19. D-glucitol, 1-deoxy-1-(methylamino)-, (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-.kappa.n1,.kappa.n4,.kappa.n7,.kappa.n10,.kappa.o1,.kappa.o4,.kappa.o7,.kappa.o10)gadolinate(1-) (1:1)
Molecular Weight | 753.9 g/mol |
---|---|
Molecular Formula | C23H42GdN5O13 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 18 |
Rotatable Bond Count | 11 |
Exact Mass | 754.20202 g/mol |
Monoisotopic Mass | 754.20202 g/mol |
Topological Polar Surface Area | 284 Ų |
Heavy Atom Count | 42 |
Formal Charge | 0 |
Complexity | 644 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 2 | |
---|---|
Drug Name | Dotarem |
PubMed Health | Gadoterate (Injection) |
Drug Classes | Diagnostic Agent, Radiopharmaceutical Imaging |
Drug Label | DOTAREM (gadoterate meglumine) is a paramagnetic macrocyclic ionic contrast agent administered for magnetic resonance imaging. The chemical name for gadoterate meglumine is D-glucitol, 1-deoxy-1-(methylamino)-,[1,4,7,10-tetraazacyclododecane-1,4,7,10... |
Active Ingredient | Gadoterate meglumine |
Dosage Form | Solution |
Route | Intravenous |
Strength | 5.6535gm/15ml (376.9mg/ml); 3.769gm/10ml (376.9mg/ml); 37.69gm/100ml (376.9mg/ml); 7.538gm/20ml (376.9mg/ml) |
Market Status | Prescription |
Company | Guerbet |
2 of 2 | |
---|---|
Drug Name | Dotarem |
PubMed Health | Gadoterate (Injection) |
Drug Classes | Diagnostic Agent, Radiopharmaceutical Imaging |
Drug Label | DOTAREM (gadoterate meglumine) is a paramagnetic macrocyclic ionic contrast agent administered for magnetic resonance imaging. The chemical name for gadoterate meglumine is D-glucitol, 1-deoxy-1-(methylamino)-,[1,4,7,10-tetraazacyclododecane-1,4,7,10... |
Active Ingredient | Gadoterate meglumine |
Dosage Form | Solution |
Route | Intravenous |
Strength | 5.6535gm/15ml (376.9mg/ml); 3.769gm/10ml (376.9mg/ml); 37.69gm/100ml (376.9mg/ml); 7.538gm/20ml (376.9mg/ml) |
Market Status | Prescription |
Company | Guerbet |
Contrast Media
Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36148
Submission : 2021-07-29
Status : Active
Type : II
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-11-06
Pay. Date : 2019-09-26
DMF Number : 34129
Submission : 2019-09-12
Status : Active
Type : II
NDC Package Code : 66499-0066
Start Marketing Date : 2019-09-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-12-30
Pay. Date : 2019-12-17
DMF Number : 34291
Submission : 2019-12-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39489
Submission : 2024-02-29
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-06-22
Pay. Date : 2022-06-02
DMF Number : 37072
Submission : 2022-05-31
Status : Active
Type : II
NDC Package Code : 14335-310
Start Marketing Date : 2022-05-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-07-29
Pay. Date : 2020-03-13
DMF Number : 34673
Submission : 2020-03-31
Status : Active
Type : II
NDC Package Code : 57884-0037
Start Marketing Date : 2020-03-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-08-28
Pay. Date : 2024-07-25
DMF Number : 38739
Submission : 2023-10-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34421
Submission : 2020-10-23
Status : Inactive
Type : II
Registrant Name : GE Healthcare AS Korea Branch
Registration Date : 2021-06-11
Registration Number : 20210611-211-J-1026
Manufacturer Name : GE Healthcare AS, Lindesnes ...
Manufacturer Address : Lindesnesveien 208, Lindesnes, NO-4521, Norway
NDC Package Code : 66499-0066
Start Marketing Date : 2019-09-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14335-310
Start Marketing Date : 2022-05-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 57884-0037
Start Marketing Date : 2020-03-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 76055-1003
Start Marketing Date : 2022-12-21
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Dotarem 15Ml
Dosage Form : INJ
Dosage Strength : 320MG/ML
Packaging : 15X1g/100ml/15ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info :
Registration Country : Ukraine
Brand Name : Dotavist
Dosage Form : Solution for Injection
Dosage Strength : 0.5mmol/ML
Packaging : 5, 10, 15, 20, 60, 100 ML Vials
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Ukraine
Regulatory Info :
Registration Country : Switzerland
Brand Name : Clariscan
Dosage Form : Inj Loose
Dosage Strength : 5.586g/20ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info : RX
Registration Country : USA
Brand Name : DOTAREM
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 37.69GM/100ML (376.9MG/ML)
Packaging :
Approval Date : 2013-03-20
Application Number : 204781
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Sweden
Brand Name : Dotarem
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 279.3 MG / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Dotarem
Dosage Form : Injection fluid, resolution
Dosage Strength : 279,3 mg/ml
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Dotarem
Dosage Form : Inj. Solution
Dosage Strength : 5.586g/20ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Canada
Brand Name : DOTAREM
Dosage Form : SOLUTION
Dosage Strength : 376.9MG/ML
Packaging : VIALS:5/10/15/20/60100ML
Approval Date :
Application Number : 2459329
Regulatory Info :
Registration Country : Canada
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Dotarem 10Ml
Dosage Form : INJ
Dosage Strength : 27.89927G/100ML/10ML
Packaging : 10X1027G/100ML/10ML
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Dotarem 20Ml
Dosage Form : INJ
Dosage Strength : 27.899g/100ml/20
Packaging : 20X1g/100ml/20
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Gadoterate Meglumine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gadoterate Meglumine, including repackagers and relabelers. The FDA regulates Gadoterate Meglumine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gadoterate Meglumine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Gadoterate Meglumine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Gadoterate Meglumine supplier is an individual or a company that provides Gadoterate Meglumine active pharmaceutical ingredient (API) or Gadoterate Meglumine finished formulations upon request. The Gadoterate Meglumine suppliers may include Gadoterate Meglumine API manufacturers, exporters, distributors and traders.
click here to find a list of Gadoterate Meglumine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Gadoterate Meglumine DMF (Drug Master File) is a document detailing the whole manufacturing process of Gadoterate Meglumine active pharmaceutical ingredient (API) in detail. Different forms of Gadoterate Meglumine DMFs exist exist since differing nations have different regulations, such as Gadoterate Meglumine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Gadoterate Meglumine DMF submitted to regulatory agencies in the US is known as a USDMF. Gadoterate Meglumine USDMF includes data on Gadoterate Meglumine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Gadoterate Meglumine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Gadoterate Meglumine suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Gadoterate Meglumine Drug Master File in Korea (Gadoterate Meglumine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Gadoterate Meglumine. The MFDS reviews the Gadoterate Meglumine KDMF as part of the drug registration process and uses the information provided in the Gadoterate Meglumine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Gadoterate Meglumine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Gadoterate Meglumine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Gadoterate Meglumine suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Gadoterate Meglumine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Gadoterate Meglumine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Gadoterate Meglumine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Gadoterate Meglumine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Gadoterate Meglumine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Gadoterate Meglumine suppliers with NDC on PharmaCompass.
Gadoterate Meglumine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gadoterate Meglumine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gadoterate Meglumine GMP manufacturer or Gadoterate Meglumine GMP API supplier for your needs.
A Gadoterate Meglumine CoA (Certificate of Analysis) is a formal document that attests to Gadoterate Meglumine's compliance with Gadoterate Meglumine specifications and serves as a tool for batch-level quality control.
Gadoterate Meglumine CoA mostly includes findings from lab analyses of a specific batch. For each Gadoterate Meglumine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gadoterate Meglumine may be tested according to a variety of international standards, such as European Pharmacopoeia (Gadoterate Meglumine EP), Gadoterate Meglumine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gadoterate Meglumine USP).
LOOKING FOR A SUPPLIER?